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Pancreatic cancer is a disease with poor prognosis mainly
due to low resection rates and late diagnosis. To increase
resectability and improve survival rates, a better understanding
of pancreatic cancer pathogenesis and more effective screening
techniques are required. New methods, such as genetic and
molecular alterations, may suggest novel approaches for pan-
creatic cancer diagnosis and treatment. We immunohistoche-
mically investigated 44 formalin-fixed, paraffin-embedded
specimens of pancreatic ductal adenocarcinoma using mono-
clonal anti-p16 antibodies and monoclonal anti-p53 antibodies.
The expressions of p16 and p53 proteins were compared using
the Chi-square test with SPSS. Disease-free survival was
analyzed using the Kaplan-Meier method, verified by the Log-
Rank test. Loss of p16 expression was noted in 20 (45.5%)
cases and aberrant p53 protein expression was detected in 14
(31.8%) cases. Loss of p16 expression was associated with a
higher incidence of lymph node metastasis (p=0.040) and a
more advanced stage (p=0.015), although there was no signifi-
cant correlation between p16 expression and survival. Aberrant
p53 protein expression correlated with histologic grade (p=
0.038). Disease-free survival rate was significantly lower in
the aberrant p53 protein positive group compared to the negative
group (p=0.029). From our results, we suggest that p53 is not
a prognostic factor; however, p16 and p53 genes do play
important roles in the progression of pancreatic ductal adeno-
carcinoma.
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INTRODUCTION
According to statistics from the 1999 Ministry of
Health Welfare of South Korea, pancreatic cancer
ranked 8
th and 10
th among cancers in incidence in
men and women, respectively, and the rate is
increasing.
1 Smoking, high-calorie diets, certain
chemical exposures, chronic pancreatitis, cystic
fibrosis, and diabetes are known to induce pan-
creatic cancer; however, no exact cause has been
identified.
2
Even after curative resection, pancreatic cancer
has a poor prognosis due to low resection rates
and late diagnosis. Only 15-20% of cases undergo
resection, and 5-year survival is approximately
20%.
3,4 In addition, adjuvant therapies have not
yet been standardized.
Several oncogenes and tumor suppressor genes
have been shown to be associated with cancer
pathogenesis, and molecular-based treatment ap-
proaches are being attempted for various cancers,
including pancreatic cancer.
5 Major genes related
to pancreatic cancer include K-ras, p53, p16, and
DPC4.
6-8
The p16 gene, also called MST1 or CDKN2, is
a tumor suppressor gene located on chromosome
9p21. By binding to cyclin-dependent kinase 4, the
p16 protein inhibits phosphorylation of various
growth and regulation factors which control pro-
liferation in the G1 period of the cell cycle. When
p16 genes are mutated, cyclin-dependent kinase 4
activation is increased and hyperphosphorylation
of Rb protein occurs, leading to accentuated pro-
gression of the cell cycle from G1 to S and to cell
proliferation.
P53 is located on chromosome 17p; it is a cell
cycle checkpoint and induces apoptosis. If p53
gene functions are inactivated, control of cell
proliferation and induction of cell apoptosis, two
major regulations in cell growth, are lost.
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Ongoing studies evaluating the association
between genes and the clinical or biological pro-
perties of pancreatic cancer have shown various
results. In addition, current studies aim to identify
the carcinogenic phase, in which various tumor
suppressor genes and oncogenes are converted
from normal cells to cancer cells.
The aims of this study were to detect p16 pro-
tein expression loss and p53 protein overexpres-
sion in pancreatic cancer using immunohisto-
chemical staining, to analyze the clinicopathologic
characteristics and their relation to survival rate
and to determine the clinical significance of p16
and p53 genes and their interaction.
MATERIALS AND METHODS
Patients diagnosed with pancreatic ductal ade-
nocarcinoma who underwent curative resection in
the Department of Surgery, Yonsei University,
College of Medicine between March 1990 and
April 1999 were eligible for the study. Ultimately,
44 subjects with appropriate paraffin-embedded
tissue samples and follow-up data were selected.
Examination of clinical records
We retrospectively examined medical and
pathological records to identify clinical and his-
topathological characteristics of subjects.
Immunohistochemical examination
p16 protein immunohistochemical staining
The 5μm serial sections of each block were
adhered to poly-L-lysine covered slides, and
heated at 50 for 1 hour. After paraffin elimina-
tion with Xylene and a staged ethyl alcohol
dehydration, sections were placed in methanol
(300 ml) and hydrogen peroxide (10 mL) for 20
minutes in order to saturate endogenous pero-
xidase. After washing in water, sections were
placed in citrate buffer solution and heated for 20
minutes. After cooling, samples were processed
with TRIS buffer solution for 10 minutes. Sections
were then incubated for 12 hours with p16 anti-
body (Santa Cruz Biotechnology, Inc, Santa Cruz,
CA, USA), diluted at a 1:100 ratio. After washing
with TRIS buffer solution, sections were stained
using the Universal LSAB peroxidase II kit (Dako,
Carpenteria, CA, USA) and developed by diami-
nobenzidine.
p53 Immunohistochemical staining
A 1:200 dilution ratio of p53 antibody
(Novocastra, Benton, NC, UK) was used for p53
immunohistochemical staining. The remaining
procedure was identical to the p16 protein
immunohistochemical staining process.
Immunohistochemical staining results
Positivity for p16 and p53 immunohistochemical
staining was microscopically determined by identi-
fication of dark brown-stained nuclei. The sample
was considered p16 or p53 protein positive in cases
that had 5% or greater positive cells from 1,000
cells under high magnifying power (×400).
Statistical analysis
p16 and p53 protein expression was compared
using the chi square test with SPSS (Chicago,
Illinois, USA). Disease-free survival was analyzed
by the Kaplan-Meier method and verified by the
Log-Rank test. A p value <0.05 was considered
significant.
RESULTS
Of the 44 subjects, there were 30 men and 14
women; the average age was 57 (range: 39 to 75)
years. Thirty-eight tumors were at the head of the
pancreas (86.4%) and 6 were in the body or tail
(13.6%); more were located at the head, as tumors
in that location have greater curative resection
possibility than those in the body or tail.
Cell types included 41 (93.2%) cases of ductal
adenocarcinoma and 3 (6.8%) cases of mucinous
ductal adenocarcinoma. Of the ductal adenocar-
cinoma cases, 6 (14.6%) were well-differentiated,
21 (51.2%) were moderately-differentiated, and 14
(34.1%) were poorly-differentiated. Size and depth
of tumor invasion classified by the American Joint
Committee on Cancer (AJCC) criteria of T1, T2,
T3, and T4 class were 3 (6.8%), 2 (4.5%), 35
(79.6%), and 4 (9.1%) cases, respectively; T3 was
the most common class in our study population.p16 and p53 in Pancreatic Cancer
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Lymph node metastasis was evident in 19 (43.2%)
cases. According to AJCC staging, the number of
patients with stage I, II, III and IV cancer were 4
(9.1%), 18 (40.9%), 18 (40.9%), and 4 (9.1%), respec-
tively (Table 1).
By immunohistochemical staining, there were
20 (45.5%) cases with negative p16 protein ex-
pression and 14 (31.8%) cases with positive p53
protein expression (Fig. 1, 2).
Negative p16 protein expression occurred in 13
(43.3%) of 30 men and 7 (50.0%) of 14 women, in-
dicating no difference between the sexes. Negative
p16 protein expression was not significantly dif-
ferent among histologic differentiation or T-
Fig. 2. Positive immunohistochemical staining for p16
protein and aberrant p53 protein. (A) p16 protein expres-
sion in pancreatic ductal adenocarcinoma. (B) aberrant
p53 protein expression in pancreatic ductal adenocarci-
noma (A and B, LSAB ×200).
Table 1. Clinicopathologic Characteristics of the 44
Patients with Pancreatic Adenocarcinoma
Parameters Number (%)
Sex
Male 30 (68.2)
Female 14 (31.8)
Location
Head 38 (86.4)
Body/tail 6 (13.6)
Cell type
Ductal adenocarcinoma 41 (93.2)
Well differentiated 6
Moderately differentiated 21
Poorly differentiated 14
Mucinous adenocarcinoma 3 (6.8)
Tumor size and depth of invasion*
T1 3 (6.8)
T2 2 (4.5)
T3 35 (79.6)
T4 4 (9.1)
Lymph node metastasis
Without 25 (56.8)
With 19 (43.2)
Stage*
I 4 (9.1)
II 18 (40.9)
III 18 (40.9)
IVA 4 (9.1)
IVB 0 (0.0)
*classified according to the American Joint Committee on Cancer
classification.
Fig. 1. Results of immunohistochemical staining of p16
and p53. Loss of p16 expression was noted in 20 (45.5%)
patients and overexpression of aberrant p53 protein was
noted in 14 (31.8%) patients.
A
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staging. Negative expression occurred in 3 (50.0%)
well-differentiated, 11 (52.4%) moderately-differ-
entiated, and 5 (35.7%) poorly-differentiated tu-
mors, and in 2 (75.0%), 1 (50.0%), 14 (40.0%), and
3 (75%) cases in T1, T2, T3, and T4 classes, respec-
tively. There was a statistically significant differ-
ence of negative p16 protein expression between
cases with and without lymphatic metastasis, 8
(32.0%) and 12 (63.2%), respectively (p=0.040).
There was also a statistically significant difference
between stage I and II vs. stage III and IV cases,
6 (27.3%) and 14 (63.6%), respectively (p=0.015)
(Table 2).
Overexpression of p53 protein was demon-
strated in 11 (36.7%) men and 3 (21.4%) women,
showing no difference among sex. With regards to
histologic differentiation, overexpression was
present in 0 (0.0%), 7 (33.3%), and 7 (50.0%) cases
with well-, moderately, and poorly differentiated
tumors, respectively; thus indicating that fre-
quency of p53 overexpression is correlated to
extent of differentiation (p=0.038). There was no
significant difference between expression of p53
protein and tumor size, depth of invasion, lymph
node metastasis, or pathologic staging (Table 3).
The overall disease-free survival rate of patients
with and without p16 protein expression was 18
and 21 months, respectively, showing no statis-
tically significant difference (Fig. 3). However,
disease-free survival of patients with and without
p53 overexpression was 10 and 24 months, respec-
tively (p=0.0209) (Fig. 4).
Table 2. Relationship between p16 Protein Expression and Clinicopathologic Characteristics of the Patients with
Pancreatic Ductal Adenocarcinoma
Parameters
p16 protein expression
p-value
Positive Negative
Sex 0.679
Male 17 13
Female 7 7
Differentiation 0.431
Well 3 3
Moderate 10 11
Poor 9 5
Tumor size and depth of invasion 0.488
T1, T2 2 3
T3, T4 22 17
Lymph node metastasis 0.040
Without 17 8
With 7 12
Stage 0.015
I, II 16 6
III, IV 8 14
Fig. 3. Disease-free survival of patients with pancreatic
ductal adenocarcinoma according to p16 protein expres-
sion.p16 and p53 in Pancreatic Cancer
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DISCUSSION
Pancreatic cancer is a deadly disease with no
effective therapy besides surgical resection. Al-
though there have been many studies, none have
yet elucidated the cause of poor prognosis in
pancreatic cancer. Due to developments in mole-
cular biology, there has been rapid progress in the
understanding of the genetic aspects of cancers.
Identifying genetic changes in cancer contributes
not only to detecting the cause of cancer, but also
to developing novel methods for diagnosis and
treatment.
The mutation of p16 genes in pancreatic cancer
is caused by homozygous deletion, point muta-
tion, or methylation of the CpG island located in
the p16 gene promoter region.
6,9,10 The incidence
of p16 gene mutation and protein expression in
pancreatic cancer has been reported between 30
and 87%,
8,10-12 with the wide range possibly
caused by a difference in subjects or examinations.
Prior studies have showed that compared to other
tissues, pancreatic cancer cell lines had more p16
gene mutation; results were different based on
mutation study methods and immunohistoche-
mical staining. The results of this study, in which
p16 protein expression was lost in 45.5% of
patients, were similar to those of previous studies.
A recent study reported that p16 genes play an
important role in the carcinogenesis of pancreatic
cancer, and Hu et al.
11 stated that comparison of
Table 3. Relationship between Aberrant p53 Protein Expression and Clinicopathologic Characteristics of the Patients
with Pancreatic Ductal Adenocarcinoma
Parameters
p53 protein expression
p-value
Positive Negative
Sex 0.312
Male 11 19
Female 3 11
Differentiation 0.038
Well 0 6
Moderate 7 14
Poor 7 7
Tumor size and depth of invasion 0.547
T1, T2 1 4
T3, T4 13 26
Lymph node metastasis 0.495
Without 9 16
With 5 14
Stage 0.414
I, II 9 13
III, IV 5 17
Fig. 4. Disease-free survival of patients with pancreatic
ductal adenocarcinoma according to aberrant p53 protein
expression.Joon Jeong, et al.
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p16 protein expression in normal pancreatic tis-
sue, acute pancreatitis, cystic tumor of the pan-
creas, and pancreatic cancer produced a signi-
ficant difference. Moskaluk et al.
13 observed that
the incidence of p16 mutation is high in early
intraductal pancreatic cancer lesions with K-ras
mutations, and stated that such mutations con-
tributed to the development of infiltrating cancer.
Another study, by Wilentz et al.
14 had similar
results, and reported that p16 genes played an im-
portant role in carcinogenesis of pancreatic cancer.
Many different results have been published
regarding p16 gene association with clinicopatho-
logic properties and survival rate. Bartsch et al.
15
stated that median survival of cases with and
without p16 mutation was 8.5 and 17 months,
respectively. However, other studies,
9,12 including
our study, found no relationship between p16
gene overexpression and survival rate. Our results
showed that loss of p16 expression is associated
with lymphatic metastasis and pathologic stage.
There are other reports showing that loss of p16
expression is associated with extent of histologic
differentiation. However, no reports have yet
demonstrated the association with lymphatic
metastasis or tumor stage. Because lymphatic
metastasis plays a critical role in discriminating
stage II from stage III, we suggest that the stages
are related to loss of p16 protein expression. Fur-
ther studies using tissue from lymphatic metasta-
sis are necessary.
Most of the p53 gene mutation in pancreatic
cancer is caused by point mutation or loss of
heterozygosity.
3 The half-life of normal p53 pro-
tein is short (10-20 minutes), but that of mutant
p53 protein is prolonged by several hours, making
it possible to detect protein by immunohisto-
chemical staining using monoclonal antibody.
The p53 mutation or p53 protein overexpression
in pancreatic cancer is reported to be 37-76%.
9,12,16-26 In our study it was 31.8%, lower than in
previous studies. Some studies have reported
association between p53 genes and the cell cycle,
and have discussed the role of p53 in the car-
cinogenesis of pancreatic cancer.
24 Zhang et al.
25
stated that p53 mutation occurs in relatively early
stages of carcinogenesis because p53 protein over-
expression is observed in intraductal papillary
adenocarcinoma. Ruggeri et al.
19 reported similar
results. However, researchers have proposed vari-
ous results in the association between p53 muta-
tion and clinicopathologic properties and survival
rate. Many researches report that there is no
association between p53 mutation and clinicopa-
thologic properties,
9,12,18-21,25 while Yokoyama et
al.
26 reported an association between p53 mutation
and clinical stages. In this study, p53 protein over-
expression was increased according to the extent
of histologic differentiation.
Because some researches report that p53 protein
expression is increased according to extent of
histologic differentiation and p53 genes control
cell cycle, it is probable that p53 mutation is asso-
ciated with cell differentiation. In effect, further
studies will be needed. Although there are many
reports showing no relationship between muta-
tion and survival, Yokoyama et al.,
26 Nakamori et
al.,
22 and this study found that subjects with p53
protein overexpression had decreased survival;
the varying results are probably due to diverse
inclusion criteria and selection bias of the studies.
Prospective randomized studies with more sub-
jects are needed to clarify this issue.
Many studies observed pancreatic cancer cases
in which p16 and p53 genes showed both varia-
tions.
27 Naumann et al.
28 reported that 77% of
patients had variations either in p16 or p53 genes.
In this study, although results were not shown, 6
cases (13.6%) had both loss of p16 protein expres-
sion and p53 overexpression, and 28 cases (63.6%)
had either. However, concurrence of p16 protein
loss and p53 overexpression failed to show clinical
significance. A genetic model, including several
genes associated with carcinogenesis could be
applied to pancreatic cancer because many genes
besides p16 and p53, such as K-ras and DPC4,
have been implicated. The interactions between
such genes has been identified to be related to
carcinogenesis. In effect, further studies, including
investigation of other tumor suppressor genes or
oncogenes apart from p16 and p53, will contribute
to the treatment of pancreatic cancer.
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